Novogen Limited (NASDAQ:KZIA) Short Interest Update

Novogen Limited (NASDAQ:KZIA) saw a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling 94,933 shares, a growth of 110.6% from the March 15th total of 45,079 shares. Based on an average trading volume of 120,681 shares, the short-interest ratio is presently 0.8 days. Currently, 5.8% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Wall Street Zen lowered shares of Novogen from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a research note on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Novogen in a research note on Wednesday, January 28th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $19.00.

Novogen Stock Down 3.1%

Shares of NASDAQ:KZIA traded down $0.28 during midday trading on Friday, reaching $8.82. The company’s stock had a trading volume of 77,244 shares, compared to its average volume of 135,314. Novogen has a twelve month low of $2.86 and a twelve month high of $17.40. The stock has a fifty day moving average of $7.24 and a 200 day moving average of $7.76.

Novogen (NASDAQ:KZIA) last released its quarterly earnings data on Saturday, February 14th. The company reported ($1.34) earnings per share for the quarter. The firm had revenue of $4.89 million for the quarter.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.